-
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Study compared two doses of dabigatran, a direct thrombin inhibitor, with warfarin for the prevention of stroke and systemic emboli in patients with nonvalvular atrial fibrillation (AF).
-
Some patients who experience stroke or transient ischemic attack (TIA) of unknown cause (i.e., cryptogenic) are subsequently found to have a patent foramen ovale (PFO).
-
Patients presenting to the emergency department (ED) with chest pain are often admitted to "rule out" myocardial infarction (MI). Many of the patients are subsequently found to have noncardiac causes of chest pain.
-
In the setting of acute ST segment elevation myocardial infarction (STEMI), warfarin is indicated for atrial fibrillation, a large dyskinetic or aneurysmal area of the left ventricle, or mural thrombus.
-
-
Angiotensin-converting enzyme inhibitor (ACEI) therapy may be beneficial during coronary artery bypass graft (CABG) surgery because of its anti-inflammatory and other vascular benefits.
-
Various risk schemes have been promulgated for assessing the risk of stroke and bleeding in patients with atrial fibrillation (AF). These investigators used the Swedish Atrial Fibrillation cohort study to investigate the comparative utility of four schemes that have been validated in AF cohorts: CHADS2, CHA2DS2-VASc, HAS-BLED, and HEMORR2HAGES.
-
-
In this paper, the authors perform a systematic review and meta-analysis of published reports comparing anticoagulation management strategies around the time of cardiac rhythm device implantation. Using standard techniques, the authors searched the medical literature and identified studies that assessed two or more anticoagulation strategies around the time of cardiac rhythm device implantation.
